---
created: 2025-04-13
updated: 2025-04-13T10:52
id: OMb?iVu|q;
specialty: pharmaco
specialty_id: 314
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::24-proteasomal-inhibitors
  - "source/ak-step1-v11:": 
  - theme/nbme::26
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/pixorize::02-biochem::22-onc-drugs::13-bortezomib,-carfilzomib
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::11-oncology::bortezomib,-carfilzomib
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::smallmoleculeinhibitors(tyrosinekinase-proteasomeinhibitors-cdkinhibitors)
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^fa-updates::fa2017
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield
type: flashcard
---

# Question
Carfilzomib and Bortezomib are examples of antineoplastics that work by inhibiting the **proteasome**

---

# Answer
Proteasome inhibitors (eg, -zomibs) = induction of neoplastic plasma cells (eg, MM) apoptosis as misfolded proteins accumulate. Pts undergoing CTh induction should be monitored for tumor lysis syndrome.    The Proteasome, an intracellular tagging system, has the ability to degrade unfolded or misfolded proteins to limit the stresses placed on the cell = allows for degradation of unwanted / used up / damaged compounds (eg. pro-apoptotic proteins)